NZ590839A - Treatment of pulmonary arterial hypertension - Google Patents

Treatment of pulmonary arterial hypertension

Info

Publication number
NZ590839A
NZ590839A NZ590839A NZ59083909A NZ590839A NZ 590839 A NZ590839 A NZ 590839A NZ 590839 A NZ590839 A NZ 590839A NZ 59083909 A NZ59083909 A NZ 59083909A NZ 590839 A NZ590839 A NZ 590839A
Authority
NZ
New Zealand
Prior art keywords
arterial hypertension
pulmonary arterial
treatment
methyl
pah
Prior art date
Application number
NZ590839A
Other languages
English (en)
Inventor
Steve Pascoe
Deborah Quinn
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41137217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ590839(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NZ590839A publication Critical patent/NZ590839A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ590839A 2008-08-13 2009-08-11 Treatment of pulmonary arterial hypertension NZ590839A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8838208P 2008-08-13 2008-08-13
US16450109P 2009-03-30 2009-03-30
PCT/US2009/053358 WO2010019540A1 (en) 2008-08-13 2009-08-11 Treatment of pulmonary arterial hypertension

Publications (1)

Publication Number Publication Date
NZ590839A true NZ590839A (en) 2013-02-22

Family

ID=41137217

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ590839A NZ590839A (en) 2008-08-13 2009-08-11 Treatment of pulmonary arterial hypertension

Country Status (16)

Country Link
US (1) US20110190313A1 (OSRAM)
EP (1) EP2315592A1 (OSRAM)
JP (1) JP2011530607A (OSRAM)
KR (1) KR20110053354A (OSRAM)
CN (1) CN102123711A (OSRAM)
AU (1) AU2009282104A1 (OSRAM)
BR (1) BRPI0917491A2 (OSRAM)
CA (1) CA2732789A1 (OSRAM)
CL (1) CL2011000295A1 (OSRAM)
IL (1) IL210922A0 (OSRAM)
MA (1) MA32617B1 (OSRAM)
MX (1) MX2011001668A (OSRAM)
NZ (1) NZ590839A (OSRAM)
RU (1) RU2011109078A (OSRAM)
TW (1) TW201010999A (OSRAM)
WO (1) WO2010019540A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2671029A1 (en) 2009-06-30 2010-12-30 James S. Baldassarre Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
CN109568319A (zh) 2013-01-10 2019-04-05 普尔莫凯恩股份有限公司 非选择性激酶抑制剂
JP6799201B2 (ja) * 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
JP6483714B2 (ja) 2013-10-11 2019-03-13 ローレンス エス． ジスマン， 噴霧乾燥製剤
JP2020500183A (ja) 2016-10-27 2020-01-09 プルモキネ、インコーポレイテッド 肺高血圧症の治療のための併用療法
US10953020B2 (en) 2016-11-08 2021-03-23 Reata Pharmaceuticals, Inc. Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof
US20210038510A1 (en) * 2018-02-08 2021-02-11 Pulmokine, Inc. Formulations of kinase inhibitors and prostanoids
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
US20200360279A1 (en) 2019-05-16 2020-11-19 Aerovate Therapeutics, Inc. Nebulized imatinib formulations, manufacture, and uses thereof
WO2021108303A1 (en) * 2019-11-25 2021-06-03 PHPrecisionMed, LLC Pharmaceutical compositions for the treatment of pulmonary hypertension
EP4210684A4 (en) * 2020-09-11 2024-10-09 Pulmosim Therapeutics LLC Compositions and methods for treating or preventing pulmonary hypertension
CA3199324A1 (en) 2020-11-17 2022-05-27 Adam Marc Silverstein Inhaled imatinib for pulmonary hypertension field

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AU2003272007A1 (en) * 2002-10-25 2004-05-13 The Administrators Of The Tulane Educational Fund Use of n-5-4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
BRPI0606872A2 (pt) * 2005-01-28 2009-07-21 Novartis Ag uso de pirimidilaminobenzamidas para o tratamento de doenças que respondem à modulação de atividade de tie-2 quinase
MX2007013738A (es) * 2005-05-02 2008-01-24 Novartis Ag Derivados de pirimidilaminobenzamida para sindrome hipereosinofilico.
EP1959957B1 (en) * 2005-12-06 2012-07-18 Novartis AG Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis
RU2009120882A (ru) * 2006-11-03 2010-12-10 Айрм Ллк (Bm) Соединения и композиции, как ингибиторы протеинкиназы

Also Published As

Publication number Publication date
RU2011109078A (ru) 2012-09-20
KR20110053354A (ko) 2011-05-20
MA32617B1 (fr) 2011-09-01
CL2011000295A1 (es) 2011-07-15
BRPI0917491A2 (pt) 2015-12-01
TW201010999A (en) 2010-03-16
WO2010019540A1 (en) 2010-02-18
US20110190313A1 (en) 2011-08-04
MX2011001668A (es) 2011-03-25
AU2009282104A1 (en) 2010-02-18
CN102123711A (zh) 2011-07-13
CA2732789A1 (en) 2010-02-18
IL210922A0 (en) 2011-04-28
JP2011530607A (ja) 2011-12-22
EP2315592A1 (en) 2011-05-04

Similar Documents

Publication Publication Date Title
NZ590839A (en) Treatment of pulmonary arterial hypertension
MY170728A (en) Treatment for diabetes in patients inappropriate for metformin therapy
HRP20120144T1 (en) Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity
MX2008013304A (es) Compuestos de peptido 1 tipo glucagon.
RU2014120792A (ru) Способ лечения стромальных опухолей желудочно-кишечного тракта
JP2011530607A5 (OSRAM)
JP2008110984A5 (OSRAM)
MX2014002471A (es) Combinaciones sinergicas de los inhibidores de p13k y mek.
MY148955A (en) Carbamoly-cyclohexanes for treating acute mania
NZ590177A (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
IN2014DN03416A (OSRAM)
NZ708802A (en) Pharmaceutical combinations comprising a protein kinase c inhibitor compound and a mitogen activated protein kinase inhibitor compound
NO20071704L (no) Prostaglandinderivater for behandling av gastrointestinal forstyrrelse
JP2009511450A5 (OSRAM)
DK1732551T3 (da) Perhexilin til behandling af kronisk hjertesvigt
ES2421587T3 (es) Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica
HRP20100265T1 (hr) Smjesa od pirimidilaminobenzamid spojeva i imatiniba za liječenje ili prevenciju proliferativnih bolesti
JP2008542390A5 (OSRAM)
MX2024009413A (es) Novedoso uso del agonista del receptor de melanocortina-1.
IL171927A0 (en) Use of tyrosine kinase inhibitor to treat diabetes
ATE504301T1 (de) Verwendung von natriumblockern zur frühzeitigen behandlung von obstruktiven lungenerkrankungen
TN2011000037A1 (en) Treatment of pulmonary arterial hypertension
CY1112203T1 (el) Καινοτομικες θεραπευτικες χρησεις της αδρενεργικης αλφουζοσινης
MX2012002910A (es) Composiciones de n-bencil-3-(4-clorofenil)-2-[metil-[2-oxo-2-(3,4, 5-trietoxifenil)acetil]amino]-n-[3-(4-piridil)-1-[2-(4-piridil)et il]propil]propanamida y usos de las misma.
MY138165A (en) Use of substituted cyclopropane acid derivatives for producing medicaments for treating the metabolic syndrome

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 11 AUG 2016 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20130531

LAPS Patent lapsed